My one dollar plus valuation refered to my ultimate valuation that I've long held - that is, I don't know the ultimate value of the company once it starts signing up contracts, but whatever it is, it's over a dollar imo (and how could it not be if monepantel is the next gen rapamycin). Your prediction of 1 cent when the company was trading in the three and four cent range in 2019 was before the big mid year rise and clearly a reference to the then sp trend, at least as far as I recall. After all, what else could you have been referring to? Clinical trial success? Commercial deals?
Ann: Commencement of Cohort 3 in Phase 1/2 MND Trial, page-39
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
22.5¢ |
Change
-0.010(4.26%) |
Mkt cap ! $89.08M | |||
| Open | High | Low | Value | Volume |
| 23.5¢ | 23.5¢ | 22.0¢ | $170.5K | 749.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 34313 | 22.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 23.5¢ | 24444 | 2 |
View Market Depth
| Last trade - 16.10pm 14/06/2024 (20 minute delay) ? |
|
|||||
|
Last
22.5¢ |
Change
-0.010 ( 6.25 %) |
||||
| Open | High | Low | Volume | ||
| 23.0¢ | 23.0¢ | 22.0¢ | 246904 | ||
| Last updated 15.57pm 14/06/2024 ? | |||||
| PAA (ASX) Chart |